These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 23348695

  • 1. Combination chemotherapy of serine protease inhibitor nafamostat mesilate with oxaliplatin targeting NF-κB activation for pancreatic cancer.
    Gocho T, Uwagawa T, Furukawa K, Haruki K, Fujiwara Y, Iwase R, Misawa T, Ohashi T, Yanaga K.
    Cancer Lett; 2013 Jun 01; 333(1):89-95. PubMed ID: 23348695
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of the NF-κB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis.
    Lu YX, Ju HQ, Wang F, Chen LZ, Wu QN, Sheng H, Mo HY, Pan ZZ, Xie D, Kang TB, Chen G, Yun JP, Zeng ZL, Xu RH.
    Cancer Lett; 2016 Sep 28; 380(1):87-97. PubMed ID: 27322737
    [Abstract] [Full Text] [Related]

  • 3. Nafamostat mesilate can prevent adhesion, invasion and peritoneal dissemination of pancreatic cancer thorough nuclear factor kappa-B inhibition.
    Fujiwara Y, Furukawa K, Haruki K, Shimada Y, Iida T, Shiba H, Uwagawa T, Ohashi T, Yanaga K.
    J Hepatobiliary Pancreat Sci; 2011 Sep 28; 18(5):731-9. PubMed ID: 21484229
    [Abstract] [Full Text] [Related]

  • 4. Anti-tumor effect by inhibition of NF-kappaB activation using nafamostat mesilate for pancreatic cancer in a mouse model.
    Furukawa K, Iida T, Shiba H, Fujiwara Y, Uwagawa T, Shimada Y, Misawa T, Ohashi T, Yanaga K.
    Oncol Rep; 2010 Oct 28; 24(4):843-50. PubMed ID: 20811662
    [Abstract] [Full Text] [Related]

  • 5. Dual inhibition of nuclear factor kappa-B and Mdm2 enhance the antitumor effect of radiation therapy for pancreatic cancer.
    Shirai Y, Shiba H, Iwase R, Haruki K, Fujiwara Y, Furukawa K, Uwagawa T, Ohashi T, Yanaga K.
    Cancer Lett; 2016 Jan 28; 370(2):177-84. PubMed ID: 26546875
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-kappaB activation.
    Uwagawa T, Chiao PJ, Gocho T, Hirohara S, Misawa T, Yanaga K.
    Anticancer Res; 2009 Aug 28; 29(8):3173-8. PubMed ID: 19661331
    [Abstract] [Full Text] [Related]

  • 8. Combination treatment using adenovirus vector-mediated tumor necrosis factor-alpha gene transfer and a NF-κB inhibitor for pancreatic cancer in mice.
    Furukawa K, Ohashi T, Haruki K, Fujiwara Y, Iida T, Shiba H, Uwagawa T, Kobayashi H, Yanaga K.
    Cancer Lett; 2011 Jul 01; 306(1):92-8. PubMed ID: 21482023
    [Abstract] [Full Text] [Related]

  • 9. Combination paclitaxel and inhibitor of nuclear factor κB activation improves therapeutic outcome for model mice with peritoneal dissemination of pancreatic cancer.
    Fujiwara Y, Furukawa K, Shimada Y, Iida T, Shiba H, Uwagawa T, Misawa T, Ohashi T, Yanaga K.
    Pancreas; 2011 May 01; 40(4):600-7. PubMed ID: 21343836
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of nuclear factor-κB enhances the antitumor effect of tumor necrosis factor-α gene therapy for hepatocellular carcinoma in mice.
    Haruki K, Shiba H, Fujiwara Y, Furukawa K, Iwase R, Uwagawa T, Misawa T, Ohashi T, Yanaga K.
    Surgery; 2013 Sep 01; 154(3):468-78. PubMed ID: 23972653
    [Abstract] [Full Text] [Related]

  • 11. Nafamostat mesilate, a nuclear factor kappa B inhibitor, enhances the antitumor action of radiotherapy on gallbladder cancer cells.
    Takada N, Sugano H, Shirai Y, Saito N, Hamura R, Taniai T, Uwagawa T, Yanaga K, Ikegami T, Ohashi T, Eto K.
    PLoS One; 2021 Sep 01; 16(9):e0257019. PubMed ID: 34473771
    [Abstract] [Full Text] [Related]

  • 12. Mechanisms of synthetic serine protease inhibitor (FUT-175)-mediated cell death.
    Uwagawa T, Li Z, Chang Z, Xia Q, Peng B, Sclabas GM, Ishiyama S, Hung MC, Evans DB, Abbruzzese JL, Chiao PJ.
    Cancer; 2007 May 15; 109(10):2142-53. PubMed ID: 17410536
    [Abstract] [Full Text] [Related]

  • 13. Combination chemotherapy of nafamostat mesylate with gemcitabine for gallbladder cancer targeting nuclear factor-κB activation.
    Iwase R, Haruki K, Fujiwara Y, Furukawa K, Shiba H, Uwagawa T, Misawa T, Ohashi T, Yanaga K.
    J Surg Res; 2013 Sep 15; 184(1):605-12. PubMed ID: 23830367
    [Abstract] [Full Text] [Related]

  • 14. Nafamostat mesilate suppresses NF-kappaB activation and NO overproduction in LPS-treated macrophages.
    Noguchi S, Nakatsuka M, Konishi H, Kamada Y, Chekir C, Kudo T.
    Int Immunopharmacol; 2003 Sep 15; 3(9):1335-44. PubMed ID: 12890431
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of nuclear factor-κB enhances the antitumor effect of paclitaxel against gastric cancer with peritoneal dissemination in mice.
    Haruki K, Shiba H, Fujiwara Y, Furukawa K, Iwase R, Uwagawa T, Misawa T, Ohashi T, Yanaga K.
    Dig Dis Sci; 2013 Jan 15; 58(1):123-31. PubMed ID: 22806547
    [Abstract] [Full Text] [Related]

  • 16. Sesquiterpene lactone parthenolide markedly enhances sensitivity of human A549 cells to low-dose oxaliplatin via inhibition of NF-kappaB activation and induction of apoptosis.
    Fang LJ, Shao XT, Wang S, Lu GH, Xu T, Zhou JY.
    Planta Med; 2010 Feb 15; 76(3):258-64. PubMed ID: 19774508
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of nuclear factor kappa-B enhances the antitumor effect of combination treatment with tumor necrosis factor-alpha gene therapy and gemcitabine for pancreatic cancer in mice.
    Fujiwara Y, Shiba H, Iwase R, Haruki K, Furukawa K, Uwagawa T, Misawa T, Ohashi T, Yanaga K.
    J Am Coll Surg; 2013 Feb 15; 216(2):320-32.e3. PubMed ID: 23219147
    [Abstract] [Full Text] [Related]

  • 18. Synergistic antitumor activity of withaferin A combined with oxaliplatin triggers reactive oxygen species-mediated inactivation of the PI3K/AKT pathway in human pancreatic cancer cells.
    Li X, Zhu F, Jiang J, Sun C, Wang X, Shen M, Tian R, Shi C, Xu M, Peng F, Guo X, Wang M, Qin R.
    Cancer Lett; 2015 Feb 01; 357(1):219-230. PubMed ID: 25444914
    [Abstract] [Full Text] [Related]

  • 19. Bortezomib-enhanced radiosensitization through the suppression of radiation-induced nuclear factor-κB activity in human oral cancer cells.
    Tamatani T, Takamaru N, Hara K, Kinouchi M, Kuribayashi N, Ohe G, Uchida D, Fujisawa K, Nagai H, Miyamoto Y.
    Int J Oncol; 2013 Mar 01; 42(3):935-44. PubMed ID: 23340716
    [Abstract] [Full Text] [Related]

  • 20. Synthetic serine protease inhibitor, gabexate mesilate, prevents nuclear factor-kappaB activation and increases TNF-alpha-mediated apoptosis in human pancreatic cancer cells.
    Takahashi H, Funahashi H, Sawai H, Matsuo Y, Yamamoto M, Okada Y, Takeyama H, Manabe T.
    Dig Dis Sci; 2007 Oct 01; 52(10):2646-52. PubMed ID: 17357832
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.